Late Stage Ocular Therapy Risks Will Eventually Reward Sustained Release Retinal Franchise Potential

Catalysts

About EyePoint

EyePoint is a biopharmaceutical company focused on sustained release ocular therapies for retinal diseases, led by its DURAVYU program in wet age related macular degeneration and diabetic macular edema.

What are the underlying business or industry changes driving this perspective?

• Although DURAVYU is aimed at two large retinal indications with a combined branded market of about US$10b, the company still depends on successful Phase III outcomes in wet AMD. Any unexpected efficacy or safety issues could limit future product revenue and delay the shift from current US$1 million quarterly net revenue to a more diversified top line.
• While the move toward treatments that reduce injection burden may support physician interest in a sustained release TKI, the need for many wet AMD patients to remain on frequent injections suggests that DURAVYU could be used more narrowly than hoped. This may cap the impact on dosing volume and overall revenue growth even if approved.
• Although the dual targeting of VEGF and IL 6 related inflammation aligns with growing recognition that retinal vascular disease is multifactorial, reliance on this differentiated mechanism means that any Phase III data that fall short of prior Phase II VERONA signals could limit pricing power and constrain future gross margin expansion.
• While EyePoint’s GMP compliant Northbridge facility and completed registration batches support potential commercial readiness, underutilization of this 41,000 square foot capacity in the event of slower than expected uptake would keep fixed manufacturing costs high relative to sales and weigh on net margins.
• Although the current cash position of over US$200 million plus the US$172 million follow on financing is expected to fund operations into Q4 2027, a prolonged period of net losses tied to Phase III costs and a possible commercial buildout without rapid revenue scaling could lead to future financing needs that dilute earnings per share.

Assumptions

This narrative explores a more pessimistic perspective on EyePoint compared to the consensus, based on a Fair Value that aligns with the bearish cohort of analysts. How have these above catalysts been quantified?

• The bearish analysts are assuming EyePoint's revenue will grow by 7.9% annually over the next 3 years.
• The bearish analysts are not forecasting that EyePoint will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate EyePoint's profit margin will increase from -486.0% to the average AU Pharmaceuticals industry of 20.9% in 3 years.
• If EyePoint's profit margin were to converge on the industry average, you could expect earnings to reach $11.1 million (and earnings per share of $0.11) by about January 2029, up from $-205.8 million today.
• In order for the above numbers to justify the price target of the more bearish analyst cohort, the company would need to trade at a PE ratio of 223.5x on those 2029 earnings, up from -6.8x today. This future PE is greater than the current PE for the AU Pharmaceuticals industry at 19.6x.
• The bearish analysts expect the number of shares outstanding to grow by 7.0% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 6.96%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

• The entire equity story is concentrated in a single late stage asset, DURAVYU. Any unfavorable Phase III efficacy or safety outcome in wet AMD or DME would hit a company that generated only US$1 million of net revenue in the latest quarter, which could severely limit future revenue growth and extend the period of net losses.
• DURAVYU targets markets currently dominated by anti VEGF biologics. If physicians are slower than expected to adopt a sustained release TKI, or restrict use to a subset of difficult cases despite the multi MOA profile, the addressable share of a US$10b retinal market could be smaller in practice, which would weigh on long term revenue and delay any path to positive earnings.
• EyePoint is scaling up a 41,000 square foot GMP facility and has produced registration batches ahead of approval. If commercial demand materializes gradually, underused manufacturing capacity could keep fixed costs elevated, capping gross margin progress and keeping net margins deeply negative for longer.
• Operating expenses of US$63 million in the latest quarter compared with US$1 million of net revenue reflect a business model still heavily geared to R&D and trial costs. If DURAVYU requires additional studies, slower regulatory timelines or broader post marketing commitments, ongoing high cash burn could force further equity raises that dilute earnings per share.
• The company expects its cash and investment balance plus US$172 million of recent financing to support operations into Q4 2027. However, any delay in key mid 2026 data readouts or in regulatory filing could push the point at which DURAVYU might start contributing meaningful revenue beyond that cash runway, increasing refinancing risk and pressure on future earnings.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The assumed bearish price target for EyePoint is $20.0, which represents up to two standard deviations below the consensus price target of $36.08. This valuation is based on what can be assumed as the expectations of EyePoint's future earnings growth, profit margins and other risk factors from analysts on the more bearish end of the spectrum.
  
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $68.0, and the most bearish reporting a price target of just $20.0.
  
• In order for you to agree with the more bearish analyst cohort, you'd need to believe that by 2029, revenues will be $53.2 million, earnings will come to $11.1 million, and it would be trading on a PE ratio of 223.5x, assuming you use a discount rate of 7.0%.
  
• Given the current share price of $16.86, the analyst price target of $20.0 is 15.7% higher.
  
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.